Kate Shaw, founder and CEO of Innovative Trials, a global clinical trial patient recruitment and retention company, won the ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab ...

Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

Gower is recognised as one of the world’s leading publishers of specialist business and management books and resources. Our publishing programme covers many of the main business processes and ...

Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...

Johnson & Johnson’s (J&J) Rybrevant (amivantamab-vmjw) combination has demonstrated a positive overall survival trend in adults with lung cancer, according to new late-stage results shared by the ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...